Antineoplastic potential of Lepisanthes rubiginosa (Roxb.) Leenh. leaves extract against ehrlich ascites carcinoma: A multi‒approach study.
- 1Department of Biochemistry and Molecular Biology, Faculty of Science, University of Rajshahi, Rajshahi, 6205, Bangladesh.
- 2Institute of Biological Sciences (IBSc), University of Rajshahi, Rajshahi, 6205, Bangladesh.
- 3Department of Genetic Engineering and Biotechnology, Faculty of Biological Science and Technology, Jashore University of Science and Technology, Jashore, 7408, Bangladesh.
Abstract
This study evaluated the antineoplastic potential of L. rubiginosa leaves by integrating phytochemical, antioxidant, in vivo, and in silico approaches. The methanolic extract of L. rubiginosa leaves (LRLME) contained high levels of phenolics (61.292 ± 0.902 mg GAE/g) and flavonoids (130.718 1.862 mg CAE/g) and exhibited strong antioxidant activity in the total antioxidant capacity, DPPH, and ABTS assays. Cytotoxicity assessment using the brine shrimp lethality assay indicated low toxicity, with an LC₅₀ of 661.278 μg/mL. In vivo antitumor studies revealed that intraperitoneal administration of LRLME (40 mg/kg) significantly inhibited Ehrlich Ascites Carcinoma (EAC) cell proliferation by 54.31% (p < 0.001) and extended the lifespan of mice implanted with tumors by 97.30% (p < 0.001). Treatment with LRLME also significantly restored hematological parameters, including red and white blood cell counts and hemoglobin levels, toward normal values compared with untreated controls. Gas chromatography-mass spectrometry (GC-MS) profiling revealed 54 phytochemical constituents, which were thereafter screened through molecular docking, ADMET profiling, and molecular dynamics simulations targeting the epidermal growth factor receptor (EGFR). Three compounds, namely (-)-norephedrine, cathine, and phenylephrine, demonstrated the highest binding affinities (-6.644, -6.474, and -6.000 kcal/mol, respectively) and favorable pharmacokinetic and toxicity profiles. Molecular dynamics studies further affirmed the sustained stable interactions and conformational stability of these compounds within the EGFR active site. Collectively, these findings suggest that L. rubiginosa exhibits significant anticancer activity against EAC cells and may serve as a potential natural reservoir of EGFR inhibitors for future therapeutic development.
Related
- In vitro and in silico therapeutic potential of Nyctanthes arbor-tristis (L.) flower extract against prostate cancer
- Dual-Component Nanoemulsion Containing Brugmansia suaveolens Leaf Extract and Copaiba Oil: Antimicrobial Activity and Preclinical Wound-Healing Potential
- Anti-neoplastic effects of Chrysanthemum indicum extract on a human hypopharyngeal squamous cell carcinoma cell line
- Bioaccessibility, anti-Helicobacter pylori activity and immunomodulatory effects of Hypogymnia physodes (L.) Nyl. extract: in vitro assessment of potential food-related applications
- Combined laboratory and field evaluation of aqueous plant extracts identifies field weed extract as a potential biostimulant for maize growth and productivity
BibTeX
@article{hasan2026antineoplastic,
title = {{Antineoplastic potential of Lepisanthes rubiginosa (Roxb.) Leenh. leaves extract against ehrlich ascites carcinoma: A multi‒approach study.}},
author = {Md Taohid Hasan and Md Shakil Ahmed and Niloy Saha and Reaz Ahmmed and Md Enamul Kabir Talukder and Nafis Fuad Shahir and Nazia Islam Rafi and Farzana Pervin and Masudul Hasan Khan and Md Rezaul Karim and Mohammad Amirul Islam},
journal = {Biochemistry and biophysics reports},
year = {2026},
month = oct,
doi = {10.1016/j.bbrep.2026.102835},
url = {https://europepmc.org/article/MED/42921219},
note = {CC BY},
}
RIS
TY - JOUR
TI - Antineoplastic potential of Lepisanthes rubiginosa (Roxb.) Leenh. leaves extract against ehrlich ascites carcinoma: A multi‒approach study.
AU - Md Taohid Hasan
AU - Md Shakil Ahmed
AU - Niloy Saha
AU - Reaz Ahmmed
AU - Md Enamul Kabir Talukder
AU - Nafis Fuad Shahir
AU - Nazia Islam Rafi
AU - Farzana Pervin
AU - Masudul Hasan Khan
AU - Md Rezaul Karim
AU - Mohammad Amirul Islam
PY - 2026
DA - 2026/10/20
JO - Biochemistry and biophysics reports
DO - 10.1016/j.bbrep.2026.102835
UR - https://europepmc.org/article/MED/42921219
AB - This study evaluated the antineoplastic potential of L. rubiginosa leaves by integrating phytochemical, antioxidant, in vivo, and in silico approaches. The methanolic extract of L. rubiginosa leaves (LRLME) contained high levels of phenolics (61.292 ± 0.902 mg GAE/g) and flavonoids (130.718 1.862 mg CAE/g) and exhibited strong antioxidant activity in the total antioxidant capacity, DPPH, and ABTS assays. Cytotoxicity assessment using the brine shrimp lethality assay indicated low toxicity, with an LC₅₀ of 661.278 μg/mL. In vivo antitumor studies revealed that intraperitoneal administration of LRLME (40 mg/kg) significantly inhibited Ehrlich Ascites Carcinoma (EAC) cell proliferation by 54.31% (p < 0.001) and extended the lifespan of mice implanted with tumors by 97.30% (p < 0.001). Treatment with LRLME also significantly restored hematological parameters, including red and white blood cell counts and hemoglobin levels, toward normal values compared with untreated controls. Gas chromatography-mass spectrometry (GC-MS) profiling revealed 54 phytochemical constituents, which were thereafter screened through molecular docking, ADMET profiling, and molecular dynamics simulations targeting the epidermal growth factor receptor (EGFR). Three compounds, namely (-)-norephedrine, cathine, and phenylephrine, demonstrated the highest binding affinities (-6.644, -6.474, and -6.000 kcal/mol, respectively) and favorable pharmacokinetic and toxicity profiles. Molecular dynamics studies further affirmed the sustained stable interactions and conformational stability of these compounds within the EGFR active site. Collectively, these findings suggest that L. rubiginosa exhibits significant anticancer activity against EAC cells and may serve as a potential natural reservoir of EGFR inhibitors for future therapeutic development.
SN - 2405-5808
ER -